We are live on ! Find out more
MTRI icon

Mentari Therapeutics, Inc. Common Stock

2 hedge funds and large institutions have $14.5K invested in Mentari Therapeutics, Inc. Common Stock in 2023 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

2.56% less ownership

Funds ownership: 3.03% → 0.47% (-2.6%)

50% less funds holding

Funds holding: 4 → 2 (-2)

100% less capital inflows, than outflows

Capital inflows: $0 | Capital outflows: $93.1K

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 2

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
2
Holders Change
-2
Holders Change %
-50%
% of All Funds
0.03%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
1
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

MTRI Hedge Fund Activity: Q2 2023 in Review

2 of the 6,391 institutional investors tracked by Wall St. Rank reported a position in Mentari Therapeutics, Inc. Common Stock (MTRI) for Q2 2023, worth a combined $14.5K — down 87% from $109K a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of MTRI and 0 opened new positions — a net loss of 2 holders — while 1 trimmed existing stakes and 0 added.

The largest seller was Renaissance Technologies, exiting entirely with an estimated $84K sold.

  • 2 institutional investors held Mentari Therapeutics, Inc. Common Stock (MTRI) as of Q2 2023, down from 4 in Q1 2023.
  • Funds reported $14.5K of Mentari Therapeutics, Inc. Common Stock stock for Q2 2023, down 87% quarter-over-quarter.
  • 0 funds opened new Mentari Therapeutics, Inc. Common Stock positions in Q2 2023 and 2 closed out, a net change of -2 holders.
  • The largest Mentari Therapeutics, Inc. Common Stock seller in Q2 2023 was Renaissance Technologies, an estimated $84K sold.

Based on aggregated 13F filings for Q2 2023.